AAVogen is a preclinical stage biotech company that develops gene therapeutics for inclusion body myositis, heart failure and other muscle wasting disease states. This includes proprietary liver de-targeted/muscle specific AAV capsids (AVGN6.1, 6.2, 6.3 & 6.4) and AVGN7; a patented gene therapeutic that prevents wasting of skeletal and cardiac muscle. Licensing opportunities are sought for the capsids while AVGN7 is being developed to treat sporadic inclusion body myositis, heart failure and rare muscle/neuromuscular diseases.